Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Psoriasis as an immune-mediated and inflammatory systemic disease: From pathophysiology to novel therapeutic approaches
10.3390/biomedicines9111511 · 2021 · External reference
The global, regional, and national burden of psoriasis: Results and insights from the Global Burden of Disease 2019 study
2021 · External reference
Global epidemiology of psoriasis: A systematic review of incidence and prevalence
10.1038/jid.2012.339 · 2013 · External reference
Investigation on the epidemiology of psoriasis in 4 provinces and cities in Southwest China (in Chinese)
2017 · External reference
An epidemiological survey of psoriasis in six provinces and cities of China (in Chinese)
2010 · External reference
Distribution of psoriasis in China: A nationwide screening
1987 · External reference
Prevalence of psoriasis in China: A population-based study in six cities
10.1684/ejd.2012.1802 · 2012 · External reference
Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021
2025 · External reference
Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management
10.1007/s13555-021-00521-z · 2021 · External reference
Psoriasis: Epidemiology, clinical features, and quality of life
10.1136/ard.2004.033217 · 2005 · External reference
Updates in psoriasis diagnosis and treatment status in China: Results from the National Psoriasis Center Registry
10.1097/cm9.0000000000002563 · 2023 · External reference
Signaling pathways and targeted therapies for psoriasis
10.1038/s41392-023-01655-6 · 2023 · External reference
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
10.1016/j.jaad.2020.07.087 · 2021 · External reference
Guidelines for the treatment of psoriasis with biologic agents in China
2021 · External reference
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
10.1016/j.jaad.2018.11.057 · 2019 · External reference
Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: A review of its mechanism, use, and clinical effectiveness
2023 · External reference
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
10.1016/j.jaad.2016.11.041 · 2017 · External reference
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial
10.1016/j.jaad.2016.11.042 · 2017 · External reference
The importance of achieving clear or almost clear skin for patients: Results from the Nordic Countries of the Global
10.2340/00015555-3048 · 2019 · External reference
Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis
10.1016/j.jaut.2009.12.001 · 2010 · External reference
Clinic characteristics of psoriasis in China: A nationwide survey in over 12000 patients
10.18632/oncotarget.18453 · 2017 · External reference
Epidemiology and treatment of psoriasis: A Chinese perspective
2014 · External reference
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
10.1111/1346-8138.14504 · 2018 · External reference
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study
10.1080/09546634.2019.1587145 · 2020 · External reference
Nail psoriasis: A review of effective therapies and recommendations for management
10.1007/s13555-021-00523-x · 2021 · External reference
Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: A narrative review
10.1007/s12325-023-02568-0 · 2023 · External reference
Cardiovascular safety of biologics targeting interleukin (IL)-12 and/or IL-23: What does the evidence say?
10.1007/s40257-021-00612-9 · 2021 · External reference
Adverse events associated with anti-IL-23 agents: Clinical evidence and possible mechanisms
10.3389/fimmu.2021.670398 · 2021 · External reference
Long-term safety of guselkumab in patients with psoriatic disease: An integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis
10.1007/s40264-023-01361-w · 2024 · External reference
Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis
10.1097/cm9.0000000000001232 · 2020 · External reference
